CRAF Gene Mutation clinical trials at UCSF

1 research study open to eligible people

The craf gene mutation can cause cells to multiply too quickly, leading to cancer. UCSF is testing the drug DCC-3084 on cancers connected to the MAPK pathway. They are exploring its effects both alone and in combination with other drugs.

Showing trials for

  • DCC-3084 in Participants With Advanced Malignancies Driven by the Mitogen-Activated Protein Kinase (MAPK) Pathway

    open to eligible people ages 18 years and up

    This is a multicenter, Phase 1/2 clinical trial to evaluate DCC-3084 alone or in combination with other cancer therapies in participants with advanced cancers. Module A will enroll participants with advanced/metastatic solid tumors. Additional modules exploring other cancers may be added to the master protocol at a later date. Each module will be conducted in 2 parts: Part 1 (Dose Escalation) and Part 2 (Dose Expansion).

    San Francisco, California and other locations

Our lead scientists for CRAF Gene Mutation research studies include .

Last updated: